VR Logo

Yumanity Therapeutics Inc. (YMTX) download report


Healthcare | Biotechnology & Pharma Research

Yumanity Therapeutics Inc. (YMTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.

IPO Date: 11-Feb-2016

CEO, Pres & Director: Dr. Richard Peters M.D., Ph.D.

Scientific Co-Founder & Sr. Advisor of Discovery Biology: Dr. Vikram Khurana M.D., Ph.D.

Listing: NASDAQ: YMTX

Country: United States

Headquarters: Boston, MA

Website: https://www.yumanity.com

Key Facts

Market cap: $18.87 Mln

Revenue (TTM): $5.53 Mln

Earnings (TTM): $-44.20 Mln

Cash: $17.46 Mln

Total Debt: $10.87 Mln

Insider's Holding: 13.65%

Liquidity: Low

52 Week range: $0.95 - 13.90

Shares outstanding: 10,842,900

Stock Performance

Time Period Yumanity Therapeutics (YMTX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-38.51-9.18-19.27
1 month65.45-4.78-8.56
3 months2.25-9.66-14.18
1 Year-83.890.81-17.70
3 Years-54.6510.335.88
5 Years-53.5511.345.74
10 Years--11.749.77
As on 30-Jun-2022 *As on 01-Jul-2022
Year Yumanity Therapeutics (YMTX) S&P Small-Cap 600 S&P BSE Sensex
2021-82.5925.2721.99
2020-62.729.5715.75
2019-29.6320.8614.38
2018-44.25-9.705.87
2017-52.4511.7327.91